Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00268892 | Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 278 | Ferring PharmaceuticalsINDUSTRY | 10 | Dec 24, 2010 | clinicaltrials |
| NCT00252941 | Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma | completed | Phase 1 / Phase 2 | 20 | The Cleveland ClinicOTHER | 1 | Dec 21, 2010 | clinicaltrials |
| NCT00116753 | A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer | completed | Phase 2 | 460 | Ferring PharmaceuticalsINDUSTRY | 11 | Dec 10, 2010 | clinicaltrials |
| NCT00004014 | Liposomal Doxorubicin in Treating Patients With Prostate Cancer | completed | Phase 2 | 10 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 16, 2010 | clinicaltrials |
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
| NCT00193193 | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Aug 4, 2010 | clinicaltrials |
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 0 | Jul 28, 2010 | clinicaltrials |
| NCT00305929 | Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure | completed | Phase 2 | 8 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00312442 | Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy | terminated | Phase 2 / Phase 3 | 16 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00181558 | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | completed | Phase 2 | 44 | Massachusetts General HospitalOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00258765 | Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. | terminated | Phase 2 | 1 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00557037 | A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer | completed | Phase 2 | 60 | MEI Pharma, Inc.INDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00003307 | Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer | completed | Phase 2 | 25 | University of ArizonaOTHER | 1 | Mar 16, 2010 | clinicaltrials |
| NCT00084526 | Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | Fox Chase Cancer CenterOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00176527 | Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 40 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00134706 | A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00136487 | Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00166725 | Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients | completed | Phase 2 | 40 | NovartisINDUSTRY | 1 | Nov 19, 2009 | clinicaltrials |
| NCT00541281 | Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer | completed | Phase 2 | 150 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Oct 27, 2009 | clinicaltrials |
| NCT00494338 | Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 6 | SanofiINDUSTRY | 1 | Oct 1, 2009 | clinicaltrials |
| NCT00895466 | Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 12 | Pepscan TherapeuticsINDUSTRY | 1 | May 8, 2009 | clinicaltrials |
| NCT00241475 | Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy | completed | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00635856 | Open Label Trial to Assess Iressa in Prostate Cancer Patients | completed | Phase 2 | 100 | AstraZenecaINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00043576 | ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere | unknown | Phase 2 / Phase 3 | 250 | NovaceaINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00200824 | Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health | completed | Phase 2 | — | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Mar 12, 2009 | clinicaltrials |
| NCT00619996 | Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer(P1) | completed | Phase 2 | 43 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00122005 | GVAX in Advanced Prostate Cancer Patients Made Lymphopenic | unknown | Phase 1 / Phase 2 | 18 | Providence Health & ServicesOTHER | 1 | Feb 24, 2009 | clinicaltrials |
| NCT00111618 | Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer | completed | Phase 2 | 70 | Antisoma ResearchINDUSTRY | 1 | Jan 30, 2009 | clinicaltrials |
| NCT00018538 | Calcifidol Therapy in Men With Cancer | completed | Phase 2 | — | US Department of Veterans AffairsFED | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00657982 | Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer | unknown | Phase 2 | 15 | Sheba Medical CenterOTHER_GOV | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00394810 | Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 2 | 21 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Nov 25, 2008 | clinicaltrials |
| NCT00090376 | Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy | completed | Phase 2 | 240 | Eisai Inc.INDUSTRY | 1 | Nov 7, 2008 | clinicaltrials |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | terminated | Phase 2 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 17, 2008 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00024414 | DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 2 | — | TheradexINDUSTRY | 1 | Jul 24, 2008 | clinicaltrials |
| NCT00087854 | Study of Individualized Amonafide to Treat Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 23, 2008 | clinicaltrials |
| NCT00108290 | Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer | completed | Phase 2 | — | US Department of Veterans AffairsFED | 1 | Apr 4, 2008 | clinicaltrials |
| NCT00278070 | Metronomic Oral Vinorelbine in Patients With Metastatic Tumors | completed | Phase 2 | — | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 29, 2008 | clinicaltrials |
| NCT00405574 | Study of ATN-224 in Patients With Prostate Cancer | unknown | Phase 2 | 50 | AttenuonINDUSTRY | 1 | Jan 30, 2008 | clinicaltrials |
| NCT00072930 | MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 2 | 150 | MedImmune LLCINDUSTRY | 7 | Jan 15, 2008 | clinicaltrials |
| NCT00140348 | Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine | completed | Phase 1 / Phase 2 | 80 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00138138 | Psychostimulants for Fatigue in Prostate Cancer | completed | Phase 2 | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2007 | clinicaltrials |
| NCT00127478 | A Long Term Safety Study With Atrasentan | completed | Phase 2 / Phase 3 | 166 | AbbottINDUSTRY | 5 | Nov 29, 2007 | clinicaltrials |
| NCT00245895 | Study of Aranesp to Treat Anemia in Prostate Cancer Patients. | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Nov 29, 2007 | clinicaltrials |
| NCT00283829 | Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Nov 29, 2007 | clinicaltrials |
| NCT00418080 | Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy | completed | Phase 2 | 86 | University of L'AquilaOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00421694 | Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide | completed | Phase 2 / Phase 3 | 119 | University of L'AquilaOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00115635 | Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 60 | Herlev HospitalOTHER | 1 | Oct 2, 2007 | clinicaltrials |
| NCT00200187 | A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery | completed | Phase 2 | 246 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Dec 24, 2010source: clinicaltrials